All the news

Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ...

People with hepatitis B who were treated with tenofovir disoproxil fumarate (TDF; Viread) were less likely to develop hepatocellular carcinoma (HCC) than those treated with entecavir (Baraclude) in a large observational study, according ...

An experimental hepatitis B virus (HBV) core protein inhibitor led to greater reductions in HBV viral load and residual HBV genetic material when added to nucleoside/nucleotide analogues, which could lead to a functional ...

Tenofovir alafenamide (TAF; Vemlidy), the new formulation of tenofovir, continues to appear at least equally effective for treatment of hepatitis B but with a better safety profile than the older tenofovir disoproxil fumarate ...

Experimental drugs that interfere with hepatitis B virus (HBV) capsid assembly continue to show promise as a new approach to antiviral treatment, according to research presented at the AASLD Liver Meeting last ...

Liver enzyme and hepatitis B 'e' antigen test results are sufficient to determine which people with hepatitis B need antiviral treatment for the infection in sub-Saharan Africa, a study carried ...